AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18260172
Drug: IV ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ibandronate (3 mg every 3 months)
Trial: 18260172
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral ibandronate (2.5 mg)
Trial: 12798874
Drug: Chemical removal
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemical removal of zona pellucida by using acidic Tyrode's solution
Trial: 10653210
Drug: Methylphenidate (20
RxNorm normalized name: methylphenidate (20/80 release) 25 mg/24 hr oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (20 mg sustained-release twice daily + 5 mg immediate-release with morning dose)
Trial: 10653210
Drug: Methylphenidate (15,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (15, 30, and 60 mg immediate-release in ascending doses)
Trial: 23011728
Drug: Remogliflozin etabonate
RxNorm normalized name: Remogliflozin etabonate
DrugBank: Remogliflozin etabonate (DB12935)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remogliflozin etabonate (50 mg)
Trial: 23011728
Drug: Remogliflozin etabonate
RxNorm normalized name: Remogliflozin etabonate
DrugBank: Remogliflozin etabonate (DB12935)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remogliflozin etabonate (150 mg)
Trial: 23011728
Drug: Remogliflozin etabonate
RxNorm normalized name: Remogliflozin etabonate
DrugBank: Remogliflozin etabonate (DB12935)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remogliflozin etabonate (500 mg)
Trial: 15639293
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (100 microg/week pegylated interferon alfa-2b and 100 mg/day lamivudine)
Trial: 15639293
Drug: Monotherapy (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (100 microg/week pegylated interferon alfa-2b and placebo)
Trial: 16640105
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy and monotherapy
Trial: 31849035
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of oral hyoscine twice daily for 1 week, followed by once daily for 1 week
Trial: 24881286
Drug: Crotamiton 10%
RxNorm normalized name: CROTAMITON 10% LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crotamiton 10% cream
Trial: 19025972
Drug: Oral topotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral topotecan at a dose of 1.2 mg/m2 twice daily for 5 days (Arm A)
Trial: 19025972
Drug: Oral topotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral topotecan once daily for 10 days (Arm B)
Trial: 29396094
Drug: Treatment-related deaths
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-related deaths
Trial: 15196585
Drug: BIBN 4096
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIBN 4096 BS (0.25, 0.5, 1, 2.5, 5, or 10 mg) administered via 10 min i.v. infusion
Trial: 9018183
Drug: Nebulized ipratropium
RxNorm normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized ipratropium bromide (500 micrograms/dose) with the first and third dose of albuterol
Trial: 8359791
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (GH) for 2 years
Trial: 25634521
Drug: Citric acid
RxNorm normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Citric acid at C3 dose
Trial: 22990631
Drug: Gastric lavage
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastric lavage with 10 ml/kg of normal saline
Trial: 11940070
Drug: Rofecoxib (cumulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib (cumulative dose of 25 mg administered in doses of 6.25 mg, 6.25 mg, and 12.5 mg)
Trial: 10080652
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg tramadol (Painlax and Tramal)
Trial: 7583525
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (rhGH) replacement therapy for 6 months
Trial: 2076716
Drug: Liposomal preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal preparation of beta‐methasone dipropionate (0.039%)
Trial: 2076716
Drug: Commercial propylene
RxNorm normalized name: propylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial propylene glycol-gel containing 0.064% beta‐methasone dipropionate
Trial: 7042366
Drug: Indoprofen (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoprofen (200 mg q.i.d.)
Trial: 7042366
Drug: Indomethacin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (25 mg q.i.d.)
Trial: 31887169
Drug: Sublingual nitroglycerin
RxNorm normalized name: nitroglycerin Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual nitroglycerin spray (800 μg, 2 puffs)
Trial: 28629180
Drug: Sausages enriched
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sausages enriched with approximately 250 mg EPA and DHA per 80 g daily for 8 weeks (n = 22)
Trial: 20728875
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg twice daily DMXB-A
Trial: 20728875
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg twice daily DMXB-A
Trial: 12626975
Drug: Low-dose LY315920Na/S-5920
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose LY315920Na/S-5920 (target plasma concentration of 200 ng/mL, n = 196)
Trial: 12626975
Drug: High-dose LY315920Na/S-5920
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose LY315920Na/S-5920 (target plasma concentration of 800 ng/mL, n = 194)
Trial: 12626975
Drug: Low-dose LY315920Na/S-5920
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose LY315920Na/S-5920 (n = 51)
Trial: 12626975
Drug: High-dose LY315920Na/S-5920
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose LY315920Na/S-5920 (n = 48)
Trial: 11735710
Drug: 0.1% tazarotene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% tazarotene cream
Trial: 11735710
Drug: 0.05% tazarotene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% tazarotene cream
Trial: 11735710
Drug: 0.025% tazarotene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.025% tazarotene cream
Trial: 11735710
Drug: 0.01% tazarotene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01% tazarotene cream
Trial: 27353466
Drug: Amoxicillin 1
RxNorm normalized name: amoxicillin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 1 g, three times daily for 7 days
Trial: 17970818
Drug: proposed treatment
RxNorm normalized name: Propoven
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: proposed treatment method
Trial: 16436240
Drug: Integrated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated treatment (assertive community treatment with family involvement and social skills training)
Trial: 10787430
Drug: margarine with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: margarine with phytosterol esters (MSE) (1.84 g/d)
Trial: 10787430
Drug: margarine with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: margarine with phytostanol esters (MSA) (1.84 g/d)
Trial: 1699400
Drug: Class I
RxNorm normalized name: HLA class I antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Class I antiarrhythmic agents (flecainide and encainide)
Trial: 1699400
Drug: Class III
RxNorm normalized name: HLA class III antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Class III antiarrhythmic agents (amiodarone)
Trial: 342629
Drug: Whole-virus vaccine
RxNorm normalized name: Rubella virus vaccine
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-virus vaccine (50 CCA units)
Trial: 342629
Drug: Whole-virus vaccine
RxNorm normalized name: Rubella virus vaccine
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-virus vaccine (two inoculations)
Trial: 335000
Drug: Split-product vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-product vaccine
Trial: 30952216
Drug: Control therapy
RxNorm normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control therapy (CTRL)
Trial: 28198465
Drug: Norepinephrine-dopamine reuptake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine-dopamine reuptake inhibitor (bupropion)
Trial: 21802026
Drug: ICX72 (Capsaicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICX72 (Capsaicin nasal spray)
Trial: 18708287
Drug: 6 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g/day arginine (ARG trial)
Trial: 22892773
Drug: 0.1 ml
RxNorm normalized name: ethanol 0.1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 ml saline solution of Propionium bacterium parvum, one dose a month for 3 to 5 months
Trial: 22892773
Drug: 0.1 ml
RxNorm normalized name: ethanol 0.1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 ml intradermal injection of placebo solution
Trial: 27117753
Drug: Desmopressin (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin (0.3 μg/kg in saline solution)
Trial: 23636302
Drug: Nicotine gum
RxNorm normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine gum (2 mg, n=42)
Trial: 23636302
Drug: Nicotine gum
RxNorm normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine gum (4 mg, n=24)
Trial: 18096304
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus injection of Sonazoid (0.6 microL microbubbles/kg body weight)
Trial: 18096304
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of Sonazoid (1.2 microL microbubbles/kg body weight over 30 min)
Trial: 18096304
Drug: Both bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both bolus injection and continuous infusion of Sonazoid
Trial: 12816354
Drug: Group E:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group E: 1.5 mL/kg, 370 mgI/mL, 5 mL/sec
Trial: 12816354
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: 100 ml, 300 mgI/mL, 3 mL/sec
Trial: 12816354
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: 2 mL/kg, 300 mgI/mL, 3 mL/sec
Trial: 12816354
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: 1.5 mL/kg, 370 mgI/mL, 3 mL/sec
Trial: 12816354
Drug: Group D:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group D: 2 mL/kg, 300 mgI/mL, 5 mL/sec
Trial: 7847251
Drug: Superselective carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Superselective carboplatin (200 mg/m2 and 300 mg/m2) with concurrent infusional 5-fluorouracil (225 mg/m2) and radiotherapy
Trial: 30968444
Drug: 500 U
RxNorm normalized name: lipase 4500 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 U C1‐INH, twice weekly for 12 weeks
Trial: 30968444
Drug: 1000 U
RxNorm normalized name: lipase 1000 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 U C1‐INH, twice weekly for 12 weeks
Trial: 30968444
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of C1‐INH
Trial: 19058059
Drug: Nasal administration
RxNorm normalized name: Novel Influenza-H1N1-09, live virus for nasal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal administration of 17beta-estradiol
Trial: 9490625
Drug: Antibodies against
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibodies against IgE and IgD; tested using ELISA with peroxidase conjugated antibodies.
Trial: 9490625
Drug: Specific IgG,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific IgG, IgM, and IgA antibodies with polysaccharide from Neisseria meningitidis serotype A; studied during vaccine testing.
Trial: 8195853
Drug: Brodimoprim (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brodimoprim (10 mg/kg on the first day, 5 mg/kg/day thereafter)
Trial: 8195853
Drug: Erythromycin (560
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (560 mg/kg/8 hours)
Trial: 8195853
Drug: Amoxicillin/clavulanic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanic acid (50 mg/kg/12 hours)
Trial: 8195853
Drug: Control groups
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control groups (Erythromycin and Amoxicillin/clavulanic acid)
Trial: 3099313
Drug: Enprostil (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enprostil (35 mcg) administered 25 min before a meal (anti-cibum AC)
Trial: 3099313
Drug: Enprostil (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enprostil (35 mcg) administered 5 min after a meal (post-cibum PC)
Trial: 3099313
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered 25 min before a meal (anti-cibum AC)
Trial: 3099313
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered 5 min after a meal (post-cibum PC)
Trial: 19651631
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose PPI therapy
Trial: 19651631
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose PPI therapy
Trial: 19651631
Drug: Gastrin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastrin (1 ng/ml) on OE33(E)(cckr) Barrett's oesophagus cells
Trial: 19651631
Drug: Gastrin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastrin (100 ng/ml) on OE33(E)(cckr) Barrett's oesophagus cells
Trial: 12085041
Drug: Magnesium Citrate
RxNorm normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium Citrate (Mg)
Trial: 12085041
Drug: Sodium Phosphate
RxNorm normalized name: Sodium Phosphate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium Phosphate (NaP) diluted into 3 doses 10 minutes apart
Trial: 2195862
Drug: Magnesium infusion
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium infusion for 48 hours
Trial: 29750828
Drug: Romosozumab 210
RxNorm normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Romosozumab 210 mg once monthly for 12 months
Trial: 15616025
Drug: Beta-cell function
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-cell function adjusted for insulin resistance
Trial: 15616025
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of FPG > or =5.6 mmol/l, BMI > or =30 kg/m(2), and family history of diabetes
Trial: 15616025
Drug: FPG >
RxNorm normalized name: Fampridine
DrugBank: Dalfampridine (DB06637)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FPG > or =6.1 mmol/l or 2-h glucose > or =7.8 mmol/l
Trial: 2698394
Drug: Lactate infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactate infusion in MVA patients
Trial: 25935960
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 5 mg/day (Control)
Trial: 16046381
Drug: Thermal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermal therapy (60 degrees C far-infrared ray dry sauna for 15 minutes, followed by bed rest with a blanket for 30 minutes, once a day, 5 days a week for 20 sessions in 4 weeks)
Trial: 16046381
Drug: Nonthermal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonthermal therapy (control group)
Trial: 9860109
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg administered orally at 0700 and 1600 hours on days 3, 4, and 5)
Trial: 7895560
Drug: Ranitidine (6.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (6.25 mg/hr continuous infusion)
Trial: 23489
Drug: Clorazepate (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clorazepate (15 mg at night)
Trial: 355663
Drug: Diazepam (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (5 mg three times a day)
Trial: 25037854
Drug: C-reactive protein
RxNorm normalized name: C-reactive protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-reactive protein (CRP) concentrations <8 mg/l
Trial: 25037854
Drug: C-reactive protein
RxNorm normalized name: C-reactive protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-reactive protein (CRP) concentrations 8-19 mg/l
Trial: 25037854
Drug: C-reactive protein
RxNorm normalized name: C-reactive protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-reactive protein (CRP) concentrations >20 mg/l
Trial: 22643937
Drug: Levobupivacaine solution
RxNorm normalized name: levobupivacaine Injectable Solution
DrugBank: Levobupivacaine (DB01002)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levobupivacaine solution
Trial: 8991488
Drug: MK-462 IV
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-462 IV doses of 5-90 micrograms kg-1
Trial: 8991488
Drug: MK-462 IV
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-462 IV doses of 60-90 micrograms kg-1
Trial: 8991488
Drug: MK-462 oral
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-462 oral 40 mg tablet without breakfast
Trial: 8991488
Drug: MK-462 oral
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-462 oral 40 mg tablet with standard breakfast
Trial: 1481177
Drug: Supplemental oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental oxygen at 2 l/min
Trial: 1481177
Drug: Supplemental oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental oxygen at 4 l/min
Trial: 1481177
Drug: Supplemental oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental oxygen at 6 l/min
Trial: 18695809
Drug: Liquid petroleum
RxNorm normalized name: liquid petroleum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid petroleum jelly (30 ml applied in the perineal region during the expulsive period)
Trial: 15991506
Drug: Remifentanil with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil with a small dose of piritramide (0.1 mg kg(‐1))
Trial: 8251280
Drug: tropisetron 5
RxNorm normalized name: tropisetron 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tropisetron 5 mg
Trial: 8815566
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) nadroparin with graduated compression stockings
Trial: 28266821
Drug: Amoxapine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxapine (50 mg daily for 4 weeks)
Trial: 28266821
Drug: Vitamin B12
RxNorm normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B12 (500 μg three-times daily for 4 weeks)
Trial: 12081816
Drug: Ground beef
RxNorm normalized name: Beef
DrugBank: Beef (DB10509)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ground beef with 2.7 g of phytosterols
Trial: 9607230
Drug: Self-administered teaching
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered teaching programme (self-training)
Trial: 29530346
Drug: Cytoreductive surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoreductive surgery with intraperitoneal chemotherapy (CRS + IPC)
Trial: 27649961
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) at 660 nm, spatial average energy fluency (SAEF) = 1.06 J/cm2, applied on postoperative days 2, 4, 6, and 8.
Trial: 27649961
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (details not specified).
Trial: 24315980
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without specific physical training, receiving respiratory therapy over 12 weeks.
Trial: 22475741
Drug: Aerosolized fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized fluticasone 880 μg twice daily for 6 weeks
Trial: 22475741
Drug: Placebo inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhaler twice daily for 6 weeks